


Nomenclature Synonyms Scleroderma Progressive Systemic Sclerosis Systemic Sclerosis

Scleroderma


 Chronic systemic autoimmune disease characterized by fibrosis of the skin as well as internal organs, e.g., lung, heart, gastrointestinal tract, and kidneys.


Limited vs. Diffuse Scleroderma


- Cutaneous criteria:
 - Limited: involves skin distal to elbows and knees, as well as face
 - <u>Diffuse</u>: involves skin of proximal extremities and face, as well as trunk
- Implications regarding natural history and prognosis


















Raynaud's Phenomenon

- Early manifestation of disease in >97% of scleroderma patients, preceding sclerodactyly by months to years
- Vasospasm of the digital microvasculature resulting in:
 - · Digital ischemia (pallor)
 - · Digital hypoxia (cyanosis)
 - · Digital reactive hyperemia (erythema)









Epidemiology of Scleroderma


- Incidence: 2 per 100,000
- Prevalence: 25-75 per 100,000
- Sex: F:M 3:1
- Racial Distribution
 - · Occurs in all populations
 - African Americans > Caucasians (2:1)
 - Choctaw Native Americans (Oklahoma)
 Prevalence: 450 per 100,000

Autoantibodies in Scleroderma

- > 98% exhibit antinuclear antibodies (+ANA)
- Limited Scleroderma
 - · 60-70% exhibit anticentromere Ab

Diffuse scleroderma

- · 30% exhibit antitopoisomerase 1 Ab (anti-Scl 70 Ab)
- · 20-30% exhibit anti-RNA polymerase Ab




Immunogenetics of Scleroderma

HLA associations:

- · Limited scleroderma (anticentromere Ab)
 - · HLA-DRβ1*0101
 - · HLA-DQβ1*0501
- · Diffuse scleroderma (antitopoisomerase 1 Ab)
 - . HLA-DRβ1*1101 (African Americans, Caucasians)
 - HLA-DRβ1*1104 (African Americans, Caucasians)
 - HLA-DQβ1*0301 (African Americans, Caucasians)
 - HLA-DRβ1*1502 (Japanese)
 HLA DR81*1603 (Chapter Network)
 - . HLA-DR β 1*1602 (Choctaw Native Americans)

Pathogenesis of Scleroderma

- Endothelial activation
 - · Vasospasm in Raynaud's disease
- Immune activation
 - · B cells and autoantibody generation
 - . T cells and HLA associations
 - Macrophages and cytokine secretion
 TGF-β, PDGF, TNFα, IL-1
- Fibroblast activation
 - . Tissue fibrosis by excessive collagen deposition



Limited vs. Diffuse Scleroderma

Kidney

Pulmonary

- Pulmonary
- Pulmonary Hypertension
- Kidney disease uncommon
- Heart disease uncommon
- Gastrointestinal
 - Esophageal dysmotility and gastroesophageal reflux disease

Pulmonary FibrosisHeart

Myocardial Fibrosis


Acute renal failure 2°


· Pulmonary Hypertension


renovascular hypertension

- Gastrointestinal
- Esophageal dysmotility and gastroesophageal reflux
- Gastroparesis
- Small bowel stasis and bacterial overgrowth
- Colonic diverticular disease

Kidney Disease in Diffuse Scleroderma
Renovascular disease causing hypertensive crisis resulting in acute renal insufficiency
Usually an early manifestation








Approach to Scleroderma Kidney Diseasae


- Prophylactic administration of Angiotensin Converting Enzyme Inhibitors (ACE inhibitors)
 - Prior to ACE inhibitors: >90% mortality within one year
 - After ACE inhibitors: >60% survival after 10 years


Pulmonary Disease*


- Parenchymal involvement (interstitial lung disease)
 Pulmonary fibrosis
- Vascular involvement
 - · Pulmonary hypertension

*Major cause of mortality in Scleroderma









Therapy of Pulmonary Hypertension

- Calcium channel blockers (e.g., diltiazem)
- Endothelin receptor blockers
 - Bosentan (Tracleer)
 - Ambrisentan (Letairis)
- Phosphodiesterase 5 inhibitor
 - Sildenafil (Revatio)
- Prostacyclin analogs
 - Epoprostenol (Flolan) intravenous
 - · Treprostinil (Remodulin) intravenous
 - · Iloprost (Ventavis) inhalation

Therapy of Interstitial Lung Disease


- Corticosteroids plus cyclophosphamide?
- Autologous stem cell transplant?


Gastrointestinal Involvement

- Principal cause of symptoms is a fibrosing process of the medial layer of the GI tract resulting in the replacement of smooth muscle with collagen
- Can involve the entire gastrointestinal tract
- Significant cause of morbidity in scleroderma


Esophageal Involvement


- Esophageal Dysmotility
 - Dysphagia
- Gastroesophageal Reflux due to incompetence of the lower esophageal sphincter
 - · Dyspepsia or heartburn













Large Intestine Involvement

- Diverticulae
 Perforation
- HypomotilityConstipation
- Pseudo-obstruction
 Abdominal pain





Approach to Gastrointestinal Disease

- Gastroesophageal reflux
 - · Antisecretory agents, e.g., proton pump inhibitors
- Malabsorption 2° to bacterial overgrowth
 Antibiotic therapy
- Hypo- or dysmotility related symptoms
 - Symptom control
 e.g., constipation → laxatives

